Metastatic Bone Pain Palliation using 177 Lu-Ethylenediaminetetramethylene Phosphonic Acid

Metastatic Bone Pain Palliation using 177 Lu-Ethylenediaminetetramethylene Phosphonic Acid

177 Lu-ethylenediaminetetramethylene phosphonic acid (EDTMP) is presently suggested as an excellent bone seeking radionuclide for developing metastatic bone pain (MBP) palliation agent owing to its suitable nuclear decay characteristics. To find the exact dosage and its efficiency, this clinical stu...

Full description

Saved in:

Bibliographic Details
Main Authors:	Mehrosadat Alavi, Shapour Omidvari, Alireza Mehdizadeh, Amir Jalilian, Ali Bahrami-Samani
Format:	Article
Language:	English
Published:	Thieme Medical and Scientific Publishers Pvt. Ltd. 2015-04-01
Series:	World Journal of Nuclear Medicine
Subjects:	177 lu-ethylenediaminetetramethylene phosphonic acid bone pain palliation metastasis nuclear medicine targeted radionuclide therapy
Online Access:	http://www.thieme-connect.de/DOI/DOI?10.4103/1450-1147.157124
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Preparation of novel zirconium phosphonates for adsorption of lutetium
by: Wanjun Mu, et al.
Published: (2022-06-01)

Comparison of tumour segmentation methods for dosimetry in [177Lu]Lu-PSMA I&T treated patients with metastatic castration resistant prostate cancer
by: Peter Frøhlich Staanum, et al.
Published: (2025-07-01)

First-in-human experience of radiopharmaceutical therapy with [177Lu]Lu-DOTATATE in patients with advanced multiple myeloma
by: Wendy Delbart, et al.
Published: (2025-07-01)

177Lu-DOTATATE peptide receptor radionuclide therapy in metastatic or advanced and inoperable primary neuroendocrine tumors of rare sites
by: Pradeep Thapa, et al.
Published: (2017-07-01)

On the feasibility of producing Lu-177 in the IEA-R1 reactor via the direct route
by: Guilherme Soares Zahn, et al.
Published: (2021-04-01)

Blood-based transcriptomic biomarkers for response to [177Lu]Lu-DOTA-TATE therapy in neuroendocrine tumors
by: Hyunpil Sung, et al.
Published: (2025-08-01)

Radiation exposure and protection advice after [177Lu]Lu-DOTA-TATE therapy in China
by: Fei Liu, et al.
Published: (2024-11-01)

Peptide receptor radionuclide therapy with 177Lu-DOTATATE for metastatic neuroendocrine tumor occurring in association with multiple endocrine neoplasia type 1 and cushing's syndrome
by: Chinna Naik, et al.
Published: (2017-04-01)

Predictors of renal function decline in patients with gastroenteropancreatic neuroendocrine tumors undergoing [177Lu]Lu-DOTA-TATE therapy
by: Felix L. Herr, et al.
Published: (2025-08-01)

USE OF <sup>177</sup>Lu-PSMA FOR RADIONUCLIDE THERAPY IN PATIENTS WITH CASTRATE-RESISTANT PROSTATE CANCER
by: A. A. Medvedeva, et al.
Published: (2021-06-01)

RM2 and DB15 analogues bearing [177Lu]Lu-DOTAGA via different linkers, as radiotherapeutics: a head-to-head comparative study
by: Panagiotis Kanellopoulos, et al.
Published: (2025-07-01)

Clinical efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy in thyroglobulin-elevated negative iodine scintigraphy: A “not-so-promising” result compared to GEP-NETs
by: Sandip Basu, et al.
Published: (2020-07-01)

Stability in the production and transport of 177Lu labelled PSMA
by: Cristian Antonio Wieczorek Villas Boas, et al.
Published: (2021-03-01)

Metastatic neuroendocrine tumor with extensive bone marrow involvement at diagnosis: Evaluation of response and hematological toxicity profile of PRRT with 177Lu-DOTATATE
by: Sandip Basu, et al.
Published: (2016-01-01)

LU-177-PSMA TREATMENT FOR METASTATIC PROSTATE CANCER – CASE EXAMPLES OF MIRACLE RESPONSES
by: K. Kairemo, et al.
Published: (2018-03-01)

Improvement of End-of-Synthesis Radiochemical Purity of <sup>177</sup>Lu-DOTA-PSMA-Ligands with Alternative Synthesis Approaches: Conversion Upswing and Side-Products Minimization
by: Anton Larenkov, et al.
Published: (2024-11-01)

Toward the standardization of radiopharmaceutical therapies: a technical note evaluating a clinical dosimetry workflow for single-time-point 177Lu SPECT/CT-based therapies
by: Taehyung Peter Kim, et al.
Published: (2025-08-01)

Robustness of textural analysis features in quantitative 99 mTc and 177Lu SPECT-CT phantom acquisitions
by: Alastair J. Gemmell, et al.
Published: (2025-04-01)

Very good effect of rescue treatment with 177Lu-DOTATATE in the patient with advanced metastatic atypical lung carcinoid
by: Małgorzata Elżbieta Poniatowska, et al.
Published: (2025-01-01)

The therapeutic use of 177 Lu-PSMA-617 radioligand therapy in prostate cancer treatment: a review of literature and ongoing trials
by: Alexander Konopnicki, et al.
Published: (2024-12-01)

The South Australian 177Lu-DOTATATE peptide receptor radionuclide therapy service: an 11-year review of toxicity, health-related quality of life, and survival
by: L.M. Altus, et al.
Published: (2025-06-01)

Investigating the significance of SPECT/CT-SUV for monitoring 177Lu-PSMA-targeted radionuclide therapy: a systematic review
by: Tahani O. Alkahtani
Published: (2025-01-01)

177Lu-DOTATATE and 177Lu-prostate-specific membrane antigen therapy in a patient with advanced metastatic radioiodine-refractory differentiated thyroid cancer after failure of tyrosine kinase inhibitors treatment
by: Majid Assadi, et al.
Published: (2019-10-01)

Is the detection of phosphonic and ethyl-phosphonic acid in organic wines an evidence of fosetyl-Al application in organic vineyards?
by: Alessandra Trinchera, et al.
Published: (2025-06-01)

Application of 68Ga‐ and 177Lu‐Labeled FAP Inhibitor in Evaluation and Treatment of Cardiac Fibrosis After Myocardial Infarction
by: Yiheng Zhao, et al.
Published: (2025-06-01)

Radiosynovectomy of Painful Synovitis of Knee Joints Due to Rheumatoid Arthritis by Intra-Articular Administration of 177 Lu-Labeled Hydroxyapatite Particulates: First Human Study and Initial Indian Experience
by: Ajit Shinto, et al.
Published: (2015-04-01)

Study of predictive factors for response to 177LU-PSMA in patients with metastatic castration-resistant prostate cancer
by: Hugo Peslier, et al.
Published: (2025-03-01)

Comparative Study of P507-impregnated Polystyrene and Polyacrylate Resins for Separation of Yb/Lu
by: FAN Xisheng, MA Guoquan, PENG Haiyue, GAO Jing, LI Feize, LAN Tu, LIAO Jiali, YANG Yuanyou, LIU Ning
Published: (2025-01-01)

177Lu-DOTATATE peptide receptor radionuclide therapy in patients with borderline low and discordant renal parameters: Treatment feasibility assessment by sequential estimation of triple parameters and filtration fraction
by: Chinna Naik, et al.
Published: (2018-01-01)

Visualization of the Spiral Ganglion Neuron in Vivo Using a Novel 177Lu Nuclear Molecule Label
by: Chenyang Kong, et al.
Published: (2025-08-01)

Dose-Dependent Cellular Phenotypic Change Induced by <sup>177</sup>Lu-Oxodotreotide Treatment in IMR-32 Cells
by: Shuai Xue, et al.
Published: (2025-06-01)

Quantitative 177Lu-DOTATATE SPECT/CT is predictive of 6-month PRRT morphological response in midgut neuroendocrine tumors: a pilot study
by: Iness Megherbi, et al.
Published: (2025-05-01)

Safety, pharmacokinetics, and dosimetry of 177Lu-AB-3PRGD2 in patients with advanced integrin αvβ3-positive tumors: A first-in-human study
by: Huimin Sui, et al.
Published: (2025-02-01)

Evaluation of using small volume of interest regions for clinical kidney dosimetry in 177Lu-DOTATATE treatments
by: Jehangir Khan, et al.
Published: (2025-07-01)

Multifactorial analysis of radiochemical purity in high-activity 177Lu-labeled theranostics: impact of precursor source, 177Lu form, and production parameters
by: William Hunt, et al.
Published: (2025-07-01)

Hematological Side Effects of <sup>177</sup>Lu-DOTA-TATE Therapy in Patients with NENs
by: Luciano Carideo, et al.
Published: (2024-12-01)

Internal Dosimetry in Patients Undergoing Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-[DOTA0-Tyr3] Octerotate: A Single-Center Experience
by: Elahe Mahmoudi, et al.
Published: (2025-01-01)

Somatostatin-receptor avidity of pancreatic neuroendocrine tumor thrombus in porto-caval venous systems on 99mTc-Octreotide and posttherapeutic 177Lu-DOTA-TATE scans
by: Mahasti Amoui, et al.
Published: (2021-07-01)

3D-Printed Organ-Realistic Phantoms to Verify Quantitative SPECT/CT Accuracy for 177Lu-PSMA-617 Treatment Planning
by: Lydia J. Wilson, et al.
Published: (2025-04-01)

Prevalence of hitherto unknown brain meningioma detected on 68Ga-DOTATATE positron-emission tomography/computed tomography in patients with metastatic neuroendocrine tumor and exploring potential of 177Lu-DOTATATE peptide receptor radionuclide therapy as single-shot treatment approach targeting both tumors
by: Rahul V. Parghane, et al.
Published: (2019-04-01)